mRNA Biology Modulators Pipeline
Anima's wholly owned disclosed pipeline of mRNA biology modulators is in Immunology (Lung fibrosis candidate advancing in preclinical stage), in Oncology (Solid tumors lead compounds entering preclinical stage and additional programs against Lymphoma and Neuroblastoma), in Neuroscience (Alzheimer's disease and Pain).
In addition to our own pipeline, we established strategic collaborations with Pharma in partnered programs including our collaborations with Lilly, Takeda Pharmaceuticals, and Abbvie.
| Indication | Target | Discovery |
Optimization |
Preclinical |
|
|---|---|---|---|---|---|
Immunology |
|||||
| Lung fibrosis | 1 | ||||
| Multiple fibrosis | 2 | ||||
| Multiple fibrosis | 3 | ||||
| Undisclosed |  |
4 | |||
Oncology |
|||||
| Solid tumors | 5 | ||||
| Solid tumors | 6 | ||||
| Leukemia | 7 | ||||
| Neuroblastoma | 8 | ||||
| Solid tumors | 9 | ||||
| Undisclosed | |
10 | |||
| Undisclosed | 11 | ||||
Neuroscience |
|||||
| Alzheimer | 12 | ||||
| Pain | 13 | ||||
| Undisclosed | 14 | ||||
| Undisclosed |  |
15 | |||
| Undisclosed | 16 | ||||
| Huntington | 17 | ||||
| Undisclosed |  |
18 | |||
| Undisclosed | 19 | ||||
| Undisclosed | 20 | ||||
| Area | Indication | Target | Discovery |
Optimization |
Preclinical |
||
|---|---|---|---|---|---|---|---|
| Immunology | Lung fibrosis | 1 | |||||
| Multiple fibrosis | 2 | ||||||
| Multiple fibrosis | 3 | ||||||
| Undisclosed | |
4 | |||||
| Oncology | Solid tumors | 5 | |||||
| Solid tumors | 6 | ||||||
| Leukemia | 7 | ||||||
| Neuroblastoma | 8 | ||||||
| Solid tumors | 9 | ||||||
| Undisclosed | |
10 | |||||
| Undisclosed | 11 | ||||||
| Neuroscience | Alzheimer | 12 | |||||
| Pain | 13 | ||||||
| Undisclosed | 14 | ||||||
| Undisclosed | |
15 | |||||
| Undisclosed | 16 | ||||||
| Huntington | 17 | ||||||
| Undisclosed | |
18 | |||||
| Undisclosed | 19 | ||||||
| Undisclosed | 20 | ||||||